您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > MMI-0100
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
MMI-0100
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:1039342-24-9
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议

产品介绍
MMI-0100 是一种细胞渗透性肽抑制剂,抑制丝裂原活化蛋白激酶活化蛋白激酶 II (MK2)。MMI-0100 在体内外减少内膜增生。MMI-0100 抑制 IL-6 表达而不影响 IL-8 表达。MMI-0100 抑制纤维化过程,例如静脉移植疾病。
Cas No.1039342-24-9
分子式C98H171N37O26
分子量2283.64
溶解度Water : 100 mg/mL (43.79 mM; Need ultrasonic)
储存条件Store at -20°C, protect from light, stored under nitrogen
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease[1].

Naphthofluorescein (compound 19) (0-10 μM; 24 hours) suppresses the HIF-1 reporter activity in a concentration-dependent manner. [1].MMI-0100 (0.25 and 0.5 mM; 24 hours) slightly increases cell proliferation in both cell types compared to control cells treated with 20 ng/ml TNF-α alone[1].MMI-0100 (1 mM) treatment also increases both EC (11%) and SMC (7%) proliferation as compared to control, this response is not as robust as that induced by treatment with 0.5 mM MMI-0100[1].MMI-0100 does not induce EC apoptosis at any dose[1].

MMI-0100 (100 μM; 28 days) inhibits intimal hyperplasia in a mouse vein graft model[1].

[1]. Akihito Muto, et al. Inhibition of Mitogen Activated Protein Kinase Activated Protein Kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. Vascul Pharmacol. Jan-Feb 2012;56(1-2):47-55.